newsfilter
← Latest News
GlobeNewswire·

Ascendis Pharma Reports Second Quarter 2026 Financial Results

– Q2 2026 product revenue of €315 million (+105% Y/Y), comprising €252 million for YORVIPATH®, €55 million for SKYTROFA®, and €8 million for YUVIWEL® – Through July 31, more than 220 unique YUVIWEL patient